PSILOCYBINE
Sponsors
Centre Hospitalier Universitaire De Nimes, Centre Hospitalier Universitaire De Nimes, Centre Hospitalier Universitaire De Nimes, Centre Hospitalier Universitaire De Nantes, Gitte Moos Knudsen, University of Zurich
Conditions
Alcohol use disorderBasic ScienceHealthyHematopoietic and Lymphatic System NeoplasmMalignant Solid NeoplasmSex addictionalcohol use disorderdepression
Phase 1
Phase 2
Psilocybin in alcohol use disorder with comorbid depression - Randomized double-blind controlled pilot study.
CompletedCTIS2023-506647-42-00
Start: 2024-02-05End: 2025-03-05Target: 30Updated: 2024-03-21
Evaluation of the effect of a single dose of psilocybin on neural correlates of cognitive control in patients with CNEP (psychogenic nonepileptic seizures): a single-arm, open-label pilot study.
Active, not recruitingCTIS2023-509679-17-00
Start: 2024-11-05Target: 10Updated: 2025-01-13
Effect of psilocybin on the positive valence system in treatment-resistant depression: a pilot clinical neuroimaging study
CompletedCTIS2022-501092-11-00
Start: 2024-11-05End: 2025-09-26Target: 20Updated: 2024-09-26
Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids
Not yet recruitingNCT06827054
Start: 2026-09-15End: 2027-05-05Target: 20Updated: 2026-08-12
A pilot TriAl of psilocybiN-Assisted psychotherapy for the treatment Of Sex addiction
Not yet recruitingCTIS2026-527083-32-00
Target: 30Updated: 2026-10-30